8±1.8 180.1±8.4 83.4±13.6
17.0±4.9 3.0±2.5 KA-H 12 19.5±1.2 181.0±6.3 81.2±8.1 12.8±4.1 4.0±2.9 CrM 12 21.3±2.8 181.3±6.4 81.8±13.8 14.2±4.7 4.3±3.4 p-level 0.07 0.91 0.90 0.08 0.55 Values are means ± selleck screening library standard deviations. One-way ANOVA revealed that there were no significant differences among groups in total upper body training volume (p = 0.89) or lower body training learn more volume (p = 0.55). MANOVA revealed no overall significant Wilks’ Lambda time (p = 0.39) or group x time (p = 0.56) interaction effects in absolute energy intake (kcal/d), protein intake (g/d), carbohydrate (g/d) or fat intake (g/d). Similar CAL-101 in vivo results were observed when assessing energy and macronutrient intake when expressed
relative to body mass. Table 5 Dietary Caloric and Macronutrient Intake Variable Group Day p-level Cediranib (AZD2171) 0 7 28 Calories (kcal/day) KA-L 2,167 ± 900 2,202 ± 653 1,998 ± 444 Group 0.29 KA-H 2,506 ± 645
2,604 ± 670 2,321 ± 677 Time 0.08 CrM 2,511 ± 582 2,372 ± 735 2,312 ± 394 G x T 0.81 Protein (g/d) KA-L 126.3 ± 76 126.2 ± 58 112.4 ± 46 Group 0.65 KA-H 139.4 ± 46 143.2 ± 54 132.5 ± 60 Time 0.05 CrM 127.8 ± 28 131.2 ± 40 114.1 ± 35 G x T 0.97 Carbohydrate (g/d) KA-L 219.1 ± 73 203.9 ± 79 181.7 ± 53 Group 0.53 KA-H 221.9 ± 74 216.0 ± 91 206.1 ± 86 Time 0.40 CrM 231.0 ± 72 226.1 ± 93 242.6 ± 66 G x T 0.38 Fat (g/d) KA-L 78.6 ± 38 84.7 ± 27 71.6 ± 16 Group 0.20 KA-H 99.2 ± 40 105.7 ± 47 94.5 ± 35 Time 0.19 CrM 91.3 ± 32 81.3 ± 30 83.0 ± 20 G x T 0.47 Calories KA-L 26.2 ± 10.0 26.6 ± 7.9 24.4 ± 7.2 Group 0.29 (kcal/kg/d) KA-H 31.4 ± 9.5 32.1 ± 10.5 28.3 ± 9.4 Time 0.06 CrM 31.2 ± 7.5 29.0 ± 8.8 28.4 ± 5.8 G x T 0.73 Protein KA-L 1.50 ± 0.8 1.52 ± 0.7 1.36 ± 0.6 Group 0.58 (g/kg/d) KA-H 1.75 ± 0.7 1.76 ± 0.8 1.61 ± 0.8 Time 0.04 CrM 1.59 ± 0.4 1.61 ± 46 1.41 ± 0.4 G x T 0.99 Carbohydrate KA-L 2.69 ± 1.0 2.48 ± 0.9 2.21 ± 0.7 Group 0.50 (g/kg/d) KA-H 2.75 ± 0.9 2.65 ± 1.2 2.46 ± 1.0 Time 0.24 CrM 2.87 ± 0.9 2.76 ± 1.1 2.99 ± 0.9 G x T 0.34 Fat KA-L 0.96 ± 0.4 1.02 ± 0.3 0.